Display options
Cite
Nedergaard A, Dalgas U, Primdahl H, et al. Collagen fragment biomarkers as serological biomarkers of lean body mass - a biomarker pilot study from the DAHANCA25B cohort and matched controls. J Cachexia Sarcopenia Muscle. 2015;6(4):335-42doi: 10.1002/jcsm.12027.
Nedergaard, A., Dalgas, U., Primdahl, H., Johansen, J., Overgaard, J., Overgaard, K., Henriksen, K., Karsdal, M. A., & Lønbro, S. (2015). Collagen fragment biomarkers as serological biomarkers of lean body mass - a biomarker pilot study from the DAHANCA25B cohort and matched controls. Journal of cachexia, sarcopenia and muscle, 6(4), 335-42. https://doi.org/10.1002/jcsm.12027
Nedergaard, Anders, et al. "Collagen fragment biomarkers as serological biomarkers of lean body mass - a biomarker pilot study from the DAHANCA25B cohort and matched controls." Journal of cachexia, sarcopenia and muscle vol. 6,4 (2015): 335-42. doi: https://doi.org/10.1002/jcsm.12027
Nedergaard A, Dalgas U, Primdahl H, Johansen J, Overgaard J, Overgaard K, Henriksen K, Karsdal MA, Lønbro S. Collagen fragment biomarkers as serological biomarkers of lean body mass - a biomarker pilot study from the DAHANCA25B cohort and matched controls. J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):335-42. doi: 10.1002/jcsm.12027. Epub 2015 Apr 22. PMID: 26673155; PMCID: PMC4670742.
Copy Download .nbib Format: NLM
Share it on

J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):335-42. doi: 10.1002/jcsm.12027. Epub 2015 Apr 22.

Collagen fragment biomarkers as serological biomarkers of lean body mass - a biomarker pilot study from the DAHANCA25B cohort and matched controls.

Journal of cachexia, sarcopenia and muscle

Anders Nedergaard, Ulrik Dalgas, Hanne Primdahl, Jørgen Johansen, Jens Overgaard, Kristian Overgaard, Kim Henriksen, Morten Asser Karsdal, Simon Lønbro

Affiliations

  1. Nordic Bioscience Biomarkers and Research Herlev, Denmark ; Institute of Sports Medicine Copenhagen (ISMC), Bispebjerg Hospital Copenhagen, Denmark.
  2. Dept. of Public Health, Section for Sports Science, Aarhus University Aarhus, Denmark.
  3. Dept. of Oncology, Aarhus University Hospital Aarhus, Denmark.
  4. Dept. of Oncology, Odense University Hospital Odense, Denmark.
  5. Dept. of Experimental Clinical Oncology, Aarhus University Hospital Aarhus, Denmark.
  6. Nordic Bioscience Biomarkers and Research Herlev, Denmark.
  7. Dept. of Public Health, Section for Sports Science, Aarhus University Aarhus, Denmark ; Dept. of Experimental Clinical Oncology, Aarhus University Hospital Aarhus, Denmark.

PMID: 26673155 PMCID: PMC4670742 DOI: 10.1002/jcsm.12027

Abstract

BACKGROUND: Loss of muscle mass and function is an important complication to ageing and a range of pathologies, including, but not restricted to, cancer, organ failures, and sepsis. A number of interventions have been proposed ranging from exercise to anabolic pharmacological therapy, with varying success. Easily applicable serological biomarkers of lean and/or muscle mass and change therein would benefit monitoring of muscle mass during muscle atrophy as well as during recovery. We set out to validate if novel peptide biomarkers derived from Collagen III and VI were markers of lean body mass (LBM) or change therein in head and neck cancer patients in the Danish Head and Neck Cancer Group(DAHANCA) 25B cohort subjected to resistance training as well as in an age-matched and gender-matched control group.

METHODS: Blood samples and dual X-ray absorptiometry data were measured at baseline, after 12 and 24 weeks in 41 HNSCC subjects of the DAHANCA 25B cohort of subjects recovering from neck and head cancer (stages provided in Table 1), and at baseline only in 21 healthy age-matched and gender-matched controls. Serum from blood was analyzed for the ProC3, IC6, and C6M peptide biomarkers and LBM were derived from the dual X-ray absorptiometry scans.

RESULTS: We were not able to show any correlation between biomarkers and LBM or C6M and anabolic response to exercise in recovering head and neck cancer patients. However, we did find that the biomarkers IC6, IC6/C6M, and ProC3 are biomarkers of LBM in the control group subjects (R (2)/P of 0.249/0.035, 0.416/0.007 and 0.178 and P = 0.057, respectively).

CONCLUSION: In conclusion, the IC6, ProC3, and IC6/C6M biomarkers are indeed biomarkers of LBM in healthy individuals of both genders, but not in HNSCC patients.

Keywords: Biomarker; Head and neck cancer; Muscle; Resistance training

References

  1. J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):1-5 - PubMed
  2. Liver Int. 2013 Mar;33(3):439-47 - PubMed
  3. Matrix Biol. 2012 Apr;31(3):187-96 - PubMed
  4. J Cachexia Sarcopenia Muscle. 2011 Mar;2(1):45-56 - PubMed
  5. Nat Commun. 2013;4:1964 - PubMed
  6. J Appl Physiol (1985). 2009 Oct;107(4):1172-80 - PubMed
  7. PLoS One. 2011;6(9):e24753 - PubMed
  8. Cancer Med. 2014 Oct;3(5):1136-45 - PubMed
  9. J Clin Endocrinol Metab. 2009 Nov;94(11):4224-33 - PubMed
  10. Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):400-7 - PubMed
  11. J Clin Densitom. 2011 Jul-Sep;14(3):294-301 - PubMed
  12. J Appl Physiol (1985). 2006 Oct;101(4):1136-48 - PubMed
  13. Osteoporos Int. 1996;6(6):432-6 - PubMed
  14. Am J Transl Res. 2013 Apr 19;5(3):303-15 - PubMed
  15. Head Neck. 2011 Jun;33(6):863-70 - PubMed
  16. Acta Oncol. 2013 Feb;52(2):310-8 - PubMed
  17. Head Neck. 2007 Oct;29(10):893-900 - PubMed
  18. Radiother Oncol. 2013 Aug;108(2):314-9 - PubMed
  19. J Cachexia Sarcopenia Muscle. 2013 Dec;4(4):267-75 - PubMed
  20. Clin Nutr. 2006 Jun;25(3):428-37 - PubMed
  21. J Clin Endocrinol Metab. 2008 Jun;93(6):2213-22 - PubMed
  22. Acta Oncol. 2013 Oct;52(7):1543-51 - PubMed
  23. Nat Rev Cancer. 2002 Nov;2(11):862-71 - PubMed

Publication Types